ライフサイエンスコーパス: preclinical study

1 ntific and therapeutic goal of a prospective preclinical study.

2 ors have shown potential for gene therapy in preclinical studies.

3 gineered livers for organ transplantation in preclinical studies.

4 ffector-attenuated bispecific antibodies for preclinical studies.

5 tion of ASD and PTSD, including clinical and preclinical studies.

6 disease, facilitating future mechanistic and preclinical studies.

7 d-beta and desirable pharmacokinetics in the preclinical studies.

8 g delivery highlighting their performance in preclinical studies.

9 s tumorigenicity and therapeutic response in preclinical studies.

10 cts of cocaine, as evidenced by clinical and preclinical studies.

11 ces and then was utilized in fundamental and preclinical studies.

12 tem-like cells for subsequent biological and preclinical studies.

13 the paucity of established models to perform preclinical studies.

14 is anti-inflammatory and neuroprotective in preclinical studies.

15 d ventricular function to DPP4 inhibition in preclinical studies.

16 and permanent noise-induced hearing loss in preclinical studies.

17 PK/PD model support the evaluation of 27 in preclinical studies.

18 l biodistribution, tumor homing, and fate in preclinical studies.

19 marker of kidney injury in both clinical and preclinical studies.

20 is insufficient rigor and reproducibility in preclinical studies.

21 lectivity and safety margins in a variety of preclinical studies.

22 promising anticancer results in a number of preclinical studies.

23 represents an unresolved gap in most of the preclinical studies.

24 ation was selected for further evaluation in preclinical studies.

25 led phase 2 and 3 trials, and also pertinent preclinical studies.

26 for the nicotine-discriminative stimulus in preclinical studies.

27 s antigens have shown promise as vaccines in preclinical studies.

28 summarizes the outcomes of both clinical and preclinical studies.

29 ain fragments (scFvs) have shown efficacy in preclinical studies.

30 therapeutic targets, as supported by strong preclinical studies.

31 e underlying pathogenetic mechanisms and for preclinical studies.

32 be developed and optimized in vitro prior to preclinical studies.

33 latform to conduct effective and large-scale preclinical studies.

34 derived cells have been investigated in many preclinical studies.

35 quality is a main cause of discrepancies in preclinical studies.

36 t enough (IC50 approximately 53 nM) to enter preclinical studies.

37 LINGO-1) has shown remyelinating activity in preclinical studies.

38 rstanding molecular mechanisms and advancing preclinical studies.

39 in cocaine addiction from both clinical and preclinical studies.

40 ive combination at reducing tumour growth in preclinical studies.

41 be effective against diverse cancer types in preclinical studies.

42 del of adult neurogenesis in comparative and preclinical studies.

43 ancer (PCa), and evaluated their efficacy in preclinical studies.

44 ized as a critical challenge in clinical and preclinical studies.

45 ance of male and female cells and animals in preclinical studies?

46 on (AMI) and chronic ischemic cardiomyopathy preclinical studies (58 studies; n=1165 mouse, rat, swin

47 on (AMI) and chronic ischemic cardiomyopathy preclinical studies (58 studies; n=1165 mouse, rat, swin

48 aCT1 is a Cx43 mimetic peptide that in preclinical studies accelerated wound closure, decreased

49 In preclinical studies, activating type 1 angiotensin (AT1)

50 xperiments as well as in ex vivo and in vivo preclinical studies after administration of 1 to rodents

51 t to include both male and female animals in preclinical studies aims to address such health disparit

52 h further development could lead to advanced preclinical studied and ultimately for lung cancer treat

53 Preclinical studies and a phase 1 study have shown that

54 HS mouse models and provide a foundation for preclinical studies and a rationale for testing whether

55 ntion and survival, as suggested by numerous preclinical studies and a small number of human studies

56 Preclinical studies and anecdotal reports show that targ

57 s to establish the overall effect of CSCs in preclinical studies and assessed translational differenc

58 well justified by the flood of evidence from preclinical studies and by the clinical success of Doxil

59 In contrast, results from some preclinical studies and cardiovascular and chemopreventi

60 In addition, preclinical studies and clinical trials demonstrate the

61 Preclinical studies and clinical trials have begun to de

62 Both preclinical studies and clinical trials have indicated t

63 disease associations have motivated numerous preclinical studies and clinical trials in search of the

64 has translated into a multitude of important preclinical studies and clinical trials that are current

65 biomarkers to evaluate treatment success in preclinical studies and clinical trials.

66 Preclinical studies and early clinical trials have confi

67 therapeutic approaches that are supported by preclinical studies and early-phase clinical trials sugg

68 has shown promise as a cancer therapeutic in preclinical studies and early-phase clinical trials.

69 practice production for use as a reagent for preclinical studies and for human clinical research.

70 e, highlight therapeutic implications of our preclinical studies and future opportunities for increti

71 nst tuberculosis over parental BCG (pBCG) in preclinical studies and has successfully completed a pha

72 Although successful preclinical studies and many positive clinical studies h

73 Our results contrast with those in preclinical studies and provide important information re

74 Based on preclinical studies and psychopharmacological interventi

75 iveness of OVs has been demonstrated in many preclinical studies and recently in humans, with US Food

76 Multiple clinical and preclinical studies and related drug discovery and devel

77 ith metastatic colorectal cancer (mCRC), but preclinical studies and retrospective clinical data sugg

78 ine is described, and key findings from both preclinical studies and the GLP-2 clinical development p

79 estigated for tolerance induction, detailing preclinical studies and the path to the clinic for many

80 cers have been synthesized, characterized in preclinical studies, and compared with the previously re

81 a promising target in tumor angiogenesis in preclinical studies, and Dll4 inhibitors have recently e

82 ous than maximum tolerated dose treatment in preclinical studies, and is currently being tested in th

83 endpoints are sufficiently robust for future preclinical studies, and that B6.Htt(Q111/+) mice are a

84 o select the most effective PrEP strategies, preclinical studies are critically needed to establish c

85 Further preclinical studies are required to assess whether hypox

86 ores in treated animals, supporting the next preclinical studies as a potential agent for the treatme

87 Preclinical studies as well as a proof-of-concept study

88 Preclinical studies as well as human neuroimaging studie

89 Most preclinical studies assess vaccine effectiveness in sing

90 tly being rigorously tested and validated in preclinical studies before they can be safely transferre

91 only overcame the supply issue for thorough preclinical studies but also paved the way for convenien

92 omising outlooks for many NP formulations in preclinical studies, but suboptimal clinical outcomes fo

93 fore the promising results from in vitro and preclinical studies can be translated to clinical succes

94 V vaccines have shown protective efficacy in preclinical studies carried out in animal models, and se

95 In preclinical studies CD276 ADCs armed with a conventional

96 On the basis of several preclinical studies, cell-based therapy has emerged as a

97 In preclinical studies, combination therapy with compound 7

98 als, we also performed a meta-analysis of 11 preclinical studies comparing efficacy of PLD and conven

99 cular perturbations of hyperammonemia; these preclinical studies complement previous studies on ammon

100 protective and neuro-regenerative effects in preclinical studies, complementing the cell replacement

101 candidate therapeutics are commonly based on preclinical studies, concern is growing regarding the re

102 In preclinical studies, davunetide promoted microtubule sta

103 Preclinical studies demonstrate that activation of NK ce

104 Previous preclinical studies demonstrate that active and passive

105 Preclinical studies demonstrate that both GLP-1R agonist

106 Preclinical studies demonstrate that glutamate homeostas

107 Many lines of preclinical studies demonstrate that neural progenitors

108 Collectively, our preclinical studies demonstrate that prostate tumor resi

109 Preclinical studies demonstrated pegvorhyaluronidase alf

110 This preclinical study demonstrates the potential of repurpos

111 an demonstration of this approach as well as preclinical studies demonstrating perturbed GSH metaboli

112 we identified five areas for improvement in preclinical study design and reporting.

113 ot been addressed is whether improvements in preclinical study design can be identified that might al

114 urs in all types of studies-animal and other preclinical studies, diagnostic studies, epidemiological

115 ndardization in the conduct and reporting of preclinical studies evaluating anticancer efficacy of th

116 Here, we review recent preclinical studies exemplifying different types of lab-

117 Progress has been made in preclinical studies, exploiting these transporters as dr

118 ve effects on social behavior indicates that preclinical studies focusing on EE as a potential treatm

119 Overall, our data highly support advanced preclinical studies for the development of Esc(1-21)-1c

120 demonstrate the value of larger, multicenter preclinical studies for vetting and prioritizing therape

121 This preclinical study forms the basis for the ongoing clinic

122 Athough preclinical studies have argued that colorectal cancer d

123 Few preclinical studies have assessed the long-term neuropat

124 selective agonists have been developed, and preclinical studies have been conducted that suggest the

125 temperature for HT is still unknown, and few preclinical studies have compared multiple HT treatment

126 Preclinical studies have consistently demonstrated incub

127 Data from clinical and preclinical studies have demonstrated controversial resu

128 The promising preclinical studies have encouraged investigators to exp

129 Preclinical studies have established its role in maintai

130 Preclinical studies have found radiotherapy enhances ant

131 Finally, these preclinical studies have helped to identify several attr

132 Preclinical studies have identified epigenetic modificat

133 However, recent preclinical studies have identified new approaches to co

134 Preclinical studies have identified other potential ther

135 Although preclinical studies have in part described this systemic

136 Preclinical studies have mostly focused on modeling righ

137 Some preclinical studies have pointed to central sites in the

138 Clinical and preclinical studies have revealed that prolonged stress

139 Imaging and preclinical studies have shown agonist-induced D2R inter

140 BACKGROUND & AIMS: Preclinical studies have shown aspirin to have anticance

141 Preclinical studies have shown convincingly in rodent mo

142 Preclinical studies have shown that aged RBCs can induce

143 Preclinical studies have shown that ginger constituents

144 Although preclinical studies have shown that Hh inhibitors block

145 Recent clinical and preclinical studies have shown that hyperkinetic disorde

146 Preclinical studies have shown that neurotrophic growth

147 extensively investigated and many promising preclinical studies have shown tumor inhibition through

148 A series of provocative preclinical studies have suggested a prominent role for

149 Preclinical studies have suggested enhanced antitumor ef

150 Preclinical studies have suggested that beta-adrenergic

151 Recent preclinical studies have suggested that it also inhibits

152 Preclinical studies have suggested that platelets influe

153 In light of recent clinical and preclinical studies highlighting the potential of inhibi

154 Recent preclinical studies, however, provide strong evidence th

155 t of type 2 diabetes are cardioprotective in preclinical studies; however, some cardiovascular outcom

156 sion and influences therapeutic responses in preclinical studies; however, specific targeted therapie

157 Preclinical studies identified Notch signaling as a prom

158 To develop such a treatment requires careful preclinical studies in a chronic epilepsy model featurin

159 Preclinical studies in a murine model of human non-Hodgk

160 Preclinical studies in AD mouse models showed that short

161 odium thiosulfate is an antioxidant shown in preclinical studies in animals to prevent cisplatin-indu

162 Results from preclinical studies in endometrial cancer show that metf

163 adjuvants elicited strong immunogenicity in preclinical studies in mice.

164 vels in the striatum is further supported by preclinical studies in non-human primates and rodents.

165 Preclinical studies in rodents and pigs indicate that th

166 alternative for an anti-inflammatory drug in preclinical studies in the near future.

167 promising as a translational bridge between preclinical study in animal models and clinical findings

168 This is the first preclinical study in which hearts, kidneys, and VCAs hav

169 Clinical and preclinical studies indicate that early postnatal exposu

170 In particular, preclinical studies indicate that females may be more se

171 Preclinical studies indicate that ketamine alters expres

172 Preclinical studies indicate that mesenchymal stem cells

173 Preclinical studies indicate that most antidepressants m

174 namide phosphoribosyltransferase (NAMPT), as preclinical studies indicate their potential efficacy as

175 indings, and previous experience translating preclinical studies into clinical application, we propos

176 Recent preclinical studies investigating cardiovascular disease

177 We focus on lessons learned from preclinical studies investigating gene suppression thera

178 The purpose of our current preclinical study is to investigate the pharmacokinetics

179 female mice with reproductive experience in preclinical studies may better reflect the life-long pat

180 ic processes including neurogenesis shown in preclinical studies may underlie these structural change

181 Design, Setting, and Participants: In this preclinical study, mice that harbor a human mutant APP g

182 Our preclinical studies motivate a future prospective clinic

183 The validity of preclinical studies of candidate therapeutic agents has

184 ing that we recommend be included in in vivo preclinical studies of drug-delivery platforms for cance

185 Here, we describe preclinical studies of liver-directed small interfering

186 d reduces alveolar edema and inflammation in preclinical studies of lung injury, but its therapeutic

187 In conclusion, the preclinical studies of ML29 as a Lassa virus vaccine can

188 e pig may be an appropriate animal model for preclinical studies of neurodegenerative diseases where

189 properties of NPs and overview in vitro and preclinical studies of organic NPs over the past 5 years

190 types that may serve as outcome measures for preclinical studies of PTHS treatments.

191 have shown progesterone to be beneficial in preclinical studies of stroke, but a progesterone dose-r

192 epresentative analogue may encourage further preclinical studies of the above-mentioned compounds.

193 The NAc is a novel target for preclinical studies of the treatment of escalated aggres

194 Preclinical studies of viral vector-based HIV-1 vaccine

195 linical practice.Significance: This detailed preclinical study of the long-term effects of widely use

196 Genetic and preclinical studies offer opportunities for treatment de

197 Here we report the first preclinical studies on pronuclear transplantation (PNT).

198 In vitro preclinical studies on purified HCL cells proved that BR

199 Preclinical studies on small molecule inhibitors of the

200 Collectively, these preclinical studies outline a CRISPR-based methodology f

201 Consistent with preclinical studies, ovarian cancers and a number of oth

202 that may be used to translate genetic and/or preclinical studies, particularly for neuropsychiatric i

203 Results of experimental and preclinical studies performed to date are reviewed.

204 In preclinical studies, pomalidomide mediated both direct a

205 Although the subject of intense preclinical study, predictive biomarkers for response an

206 tially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brai

207 In a subset of 1681 preclinical studies, randomization, blinding, sample siz

208 ices and consider some new ones, focusing on preclinical studies relevant to human neurological and p

209 first, issues regarding trial rationale and preclinical study results; second, pharmacological issue

210 Through review of preclinical studies, retrospective clinical studies, and

211 Preclinical studies reveal a number of neurotransmitter

212 Preclinical studies revealed contribution of N-methyl-D-

213 Preclinical studies revealed that GLV-1h68 combined with

214 After years of preclinical studies, several clinical trials for SCD gen

215 ockade is used for many pain conditions, but preclinical studies show both pro- and anti-nociceptive

216 In summary, preclinical studies show SGN-CD19B is a highly active AD

217 Preclinical studies show that arginine deprivation is sy

218 Preclinical studies showed significant disease regressio

219 Preclinical studies showed that new-generation humanized

220 Recent preclinical studies showed the potential of nicotinamide

221 Although this view is consistent with preclinical studies showing a negative impact of prefron

222 Motivated by findings from preclinical studies showing potent synergistic activity

223 f tissue-engineered grafts is critical, with preclinical studies showing that seeding scaffolds with

224 sed on our findings, and coupled with recent preclinical studies showing the importance of multiple n

225 Additionally, we highlight preclinical studies showing the potential of genome edit

226 Supporting preclinical studies span decades, but are often overlook

227 Preclinical studies suggest a facilitatory role for infl

228 Although preclinical studies suggest LABAs and LAMAs have antiinf

229 The results of preclinical studies suggest that anesthetic drugs admini

230 Both clinical and preclinical studies suggest that antiamyloid strategies

231 Preclinical studies suggest that augmenting N-methyl-d-a

232 Although preclinical studies suggest that CD73 can be targeted fo

233 Preclinical studies suggest that cell-based intervention

234 Findings from preclinical studies suggest that dipeptidyl peptidase-4

235 Preclinical studies suggest that elevating the cGMP intr

236 Preclinical studies suggest that extracellular signal-re

237 Preclinical studies suggest that hospitalized patients a

238 Preclinical studies suggest that neural function, neural

239 Preclinical studies suggest that noncytotoxic concentrat

240 Preclinical studies suggest that P2X3 receptors are expr

241 Preclinical studies suggest that programmed death 1 (PD-

242 Preclinical studies suggest that Reed-Sternberg cells ex

243 g resistance to existing agents are complex, preclinical studies suggest that selective estrogen rece

244 Preclinical studies suggest that stress activates beta-a

245 Recent preclinical studies suggest that the susceptibility to a

246 have the ability to create new heart tissue, preclinical studies suggest that these cells release car

247 These preclinical studies suggest that, so far, this unimolecu

248 Our preclinical study suggests that ganetespib and doxorubic

249 Preclinical studies support the efficacy of mesenchymal

250 This preclinical study supports the concept that reduced toxi

251 I discuss preclinical studies targeting Fyn as a therapeutic inter

252 for investigating the function of hCD22 and preclinical studies targeting hCD22.

253 Preclinical studies targeting the adenosinergic pathway

254 Finally, preclinical studies tend to more consistently support th

255 We review preclinical studies that have directly targeted prefront

256 review also highlights several clinical and preclinical studies that offer mechanistic insights into

257 ity to elucidate natural history and perform preclinical studies that test new treatments in the cont

258 hers to actually bench test and evaluate, in preclinical studies, the efficacy of new therapeutic str

259 In preclinical studies, the tracer showed excellent initial

260 In this preclinical study, the SSTR2 antagonist OPS201 (DOTA-JR1

261 In keeping with preclinical studies, these human findings suggest that t

262 In preclinical studies, these rules led to disclosure of mu

263 In preclinical studies, these synergistic effects of TSEC o

264 ng agents are showing anti-tumor activity in preclinical studies, they are not effective in all the p

265 ists also increase pancreatic weight in some preclinical studies through poorly understood mechanisms

266 n the translation of mechanisms derived from preclinical studies to complementary findings in clinica

267 1 antagonist) was compared with SB-705498 in preclinical studies to establish whether an improved eff

268 We used available sunitinib preclinical studies to evaluate relationships between st

269 aques (Macaca mulatta) are routinely used in preclinical studies to evaluate therapeutic Abs and cand

270 treatments, led to more direct bridging from preclinical studies to human trials than the conventiona

271 L-HCC, and establishes a practical model for preclinical studies to identify strategies to treat this

272 effective in t(8;21) AML patients, rigorous preclinical studies to identify the molecular and biolog

273 period when this drug was transitioning from preclinical studies to phase I clinical trial status.

274 ine transporter (VAChT) and has been used in preclinical studies to quantify presynaptic cholinergic

275 genitor cells and the pipeline starting from preclinical studies to the designs of phase I and IIa cl

276 andidate treatment in cancer control require preclinical studies to validate the biological efficacy

277 In preclinical studies, treating vemurafenib-resistant mela

278 r pharmacogenomics discovery is conducted in preclinical studies, typically using cell lines and mous

279 Preclinical studies using a variety of approaches to red

280 Preclinical studies using different mouse models of T2DM

281 Preclinical studies using genetically engineered mouse m

282 In preclinical studies using orthotopic models, NCL-1 and N

283 This clinical scenario is modeled in preclinical studies using the context-induced reinstatem

284 or dual-tropic virus infection ex vivo In a preclinical study using hu-PBL mice, we show that CD4 T

285 Taken together, these preclinical studies validate the PLK1-PAX3-FOXO1 axis as

286 In preclinical studies, venetoclax enhanced bortezomib acti

287 The aim of the present preclinical studies was to achieve high and persistent s

288 A preclinical study was performed in a test population of

289 The aim of this preclinical study was to establish the functional profil

290 The purpose of this preclinical study was to further explore the use of NeoB

291 use of male and female cells and animals in preclinical studies, we explored whether sex bias exists

292 Based on human and preclinical studies, we hypothesized that a combination

293 Focusing on preclinical studies, we review the existing evidence for

294 In this preclinical study, we first demonstrate that a mouse mod

295 In this preclinical study, we further investigated whether the a

296 In this preclinical study, we used eight human breast cancer cel

297 In this preclinical study, we used MRE to quantify (kPa) the ela

298 seases are usually not taken into account in preclinical studies, which predominantly use young, heal

299 Here, we describe preclinical studies with an Fc engineered IgA2m(1) antib

300 that have demonstrated promising results in preclinical studies with the potential for clinical appl